Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ERBB2 L786V |
Gene Variant Detail | |
Relevant Treatment Approaches | HER inhibitor (Pan) HER2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ERBB2 L786V | lung non-small cell carcinoma | no benefit | HER2 Inhibitor | Neratinib | Case Reports/Case Series | Actionable | In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.7 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L786V (PMID: 29420467; NCT01953926). | 29420467 |
ERBB2 L786V | Advanced Solid Tumor | resistant | HER2 Inhibitor | Sapitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L786V were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020). | 31588020 |
ERBB2 L786V | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) L786V in culture (PMID: 31588020). | 31588020 | |
ERBB2 L786V | Advanced Solid Tumor | resistant | HER2 Inhibitor | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L786V were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
ERBB2 L786V | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) inhibited survival of transformed cells expressing ERBB2 (HER2) L786V in culture (PMID: 31588020). | 31588020 |
ERBB2 L786V | Advanced Solid Tumor | sensitive | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tagrisso (osimertinib) inhibited survival of transformed cells expressing ERBB2 (HER2) L786V in culture (PMID: 31588020). | 31588020 | |
ERBB2 L786V | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Imbruvica (ibrutinib) inhibited survival of transformed cells expressing ERBB2 (HER2) L768V in culture (PMID: 31588020). | 31588020 |
ERBB2 L786V | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Poziotinib (HM781-36B) inhibited survival of transformed cells expressing ERBB2 (HER2) L786V in culture (PMID: 31588020). | 31588020 |
ERBB2 L786V | Advanced Solid Tumor | sensitive | HER2 Inhibitor | TH-4000 | Preclinical - Cell culture | Actionable | In a preclinical study, Tarloxotinib (TH-4000) inhibited survival of transformed cells expressing ERBB2 (HER2) L786V in culture (PMID: 31588020). | 31588020 |
ERBB2 L786V | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vizimpro (dacomitinib) inhibited survival of transformed cells expressing ERBB2 (HER2) L786V in culture (PMID: 31588020). | 31588020 |
ERBB2 L786V | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Pyrotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pyrotinib inhibited survival of transformed cells expressing ERBB2 (HER2) L786V in culture (PMID: 31588020). | 31588020 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Recruiting |